Detalhe da pesquisa
1.
CYD Tetravalent Dengue Vaccine Performance by Baseline Immune Profile (Monotypic/Multitypic) in Dengue-Seropositive Individuals.
Clin Infect Dis
; 72(10): 1730-1737, 2021 05 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-32198515
2.
Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America.
Clin Infect Dis
; 73(6): 1003-1012, 2021 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33822015
3.
Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy.
N Engl J Med
; 379(4): 327-340, 2018 Jul 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-29897841
4.
The Effects of Japanese Encephalitis Vaccine and Accelerated Dosing Scheduling on the Immunogenicity of the Chimeric Yellow Fever Derived Tetravalent Dengue Vaccine: A Phase II, Randomized, Open-Label, Single-Center Trial in Adults Aged 18 to 45 Years in the United States.
J Infect Dis
; 221(7): 1057-1069, 2020 03 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-31755526
5.
Impact of Dengue Vaccination on Serological Diagnosis: Insights From Phase III Dengue Vaccine Efficacy Trials.
Clin Infect Dis
; 66(8): 1164-1172, 2018 04 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29300876
6.
Dissecting Antibodies Induced by a Chimeric Yellow Fever-Dengue, Live-Attenuated, Tetravalent Dengue Vaccine (CYD-TDV) in Naive and Dengue-Exposed Individuals.
J Infect Dis
; 215(3): 351-358, 2017 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27932620
7.
Immune response to live-attenuated Japanese encephalitis vaccine (JE-CV) neutralizes Japanese encephalitis virus isolates from south-east Asia and India.
BMC Infect Dis
; 14: 156, 2014 Mar 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-24656175
8.
Beta-variant recombinant booster vaccine elicits broad cross-reactive neutralization of SARS-CoV-2 including Omicron variants.
Heliyon
; 10(5): e27033, 2024 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38486776
9.
Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study.
EClinicalMedicine
; 62: 102109, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37533419
10.
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 Protein Vaccine.
medRxiv
; 2023 Jan 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-36523415
11.
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial.
Lancet Respir Med
; 11(11): 975-990, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37716365
12.
Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, multi-country study.
EClinicalMedicine
; 64: 102168, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37936652
13.
Vaccine-induced antibodies to contemporary strains of dengue virus type 4 show a mechanistic correlate of protective immunity.
Cell Rep
; 39(10): 110930, 2022 06 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35675766
14.
Accuracy and efficacy of pre-dengue vaccination screening for previous dengue infection with a new dengue rapid diagnostic test: a retrospective analysis of phase 3 efficacy trials.
Lancet Microbe
; 3(6): e427-e434, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35659904
15.
Performance Evaluation of a Dengue IgG Rapid Diagnostic Test Designed to Determine Dengue Serostatus as Part of Prevaccination Screening.
Microbiol Spectr
; 10(3): e0071121, 2022 06 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-35604130
16.
Whole-blood cytokine secretion assay as a high-throughput alternative for assessing the cell-mediated immunity profile after two doses of an adjuvanted SARS-CoV-2 recombinant protein vaccine candidate.
Clin Transl Immunology
; 11(1): e1360, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35035955
17.
Repeated Rapid Active Sampling Surveys Demonstrated a Rapidly Changing Zika Seroprevalence among Children in a Rural Dengue-endemic Region in Southwest Guatemala during the Zika Epidemic (2015-2016).
Am J Trop Med Hyg
; 107(5): 1099-1106, 2022 11 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36252798
18.
Immunogenicity and safety of booster CYD-TDV dengue vaccine after alternative primary vaccination schedules in healthy individuals aged 9-50 years: a randomised, controlled, phase 2, non-inferiority study.
Lancet Infect Dis
; 22(6): 901-911, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35364022
19.
Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study.
Lancet Infect Dis
; 22(5): 636-648, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35090638
20.
Dengue vaccine breakthrough infections reveal properties of neutralizing antibodies linked to protection.
J Clin Invest
; 131(13)2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34003796